Yuhan | Sustainability Performance
Develops, manufactures, and markets pharmaceutical and healthcare products. Offers prescription drugs, over-the-counter products, and medical solutions while supporting research, development, and distribution channels in healthcare.
1926
South Korea
1,001 - 5,000 employees
Pharmaceuticals
$1B - 10B in revenue
$100M - 500M in profitability
Submit or report inaccurate dataDownload Company InsightsⓘBy downloading this report, you'll receive the most insightful and detailed analysis of the company's sustainability performance, compared to its peers. It includes key industry trends, carbon and energy intensity, nature impact, social metrics, and an in-depth look at key risks and controversies.
Sustainability Ranking & Industry Benchmark
#6097
Overallⓘ#83
in South Koreaⓘ#145
in PharmaceuticalsⓘSustainability Maturity
ⓘSustainability Intent
ⓘOverview
Environmental
Carbon emissionsEnergy consumptionWaste ManagementWater ManagementAir & land impactNature and biodiversitySocial
Diversity and InclusionPay GapsExternalitiesGovernance
SDG ImpactFinancial Data
Business performanceCapital & innovationAnalyst projections
Aligned
Aligned
Critical
Intensity
Energy consumption (direct) intensity (MWh /$M)
Water consumption intensity (m³ /$M)
Waste generation intensity (tonnes /$M)
Industry Benchmark
92.4
B/M 42.0
95.7
B/M 131.1
1.1
B/M 0.4
Powered by illuminem and GIST Impact
Controversy level
- Yuhan Corporation, Korean major pharma (lazertinib/leclaza YuhanJanssen licensing), has faced sustained Korean FSC enforcement scrutiny over the contested historic 2018 USD 1.55 billion YuhanJanssen lazertinib licensing deal and the sustained 2024 Janssen Rybrevant/Lazcluze approval pressure affecting Korean institutional shareholders.
